Interestingly, miR-493-5p targeted both NFATC1 and CCNA2 for silencing, linking two branches of the cell senescence pathway not described by KEGG; considering that this miRNA is normally found suppressed in prostate cancer [112], it makes miR-493-5p a good potential therapeutic target for prostate cancer treatment. This evidence concerns the gene CCNA2 and Familial prostate cancer.